It is more than a year away from getting approval to treat pain from bone cancer lesions and is targeting prostate, breast and brain tumors.

FORBES: Magazine Article

The second thing that we learned is that we were not able to show an impact on time to disease progression in the way that we measured it, which was the time to the next progression event or two lesions in the bone.

FORBES: The Man Behind The First Cancer-Treating Vaccine On The FDA And Innovation